Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
NCT07321912Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eflornithine in Ewing sarcoma, osteosarcoma (OS), sponsored by Penn State Health Milton S. Hershey Medical Center. Started Jun 2026; status: recruiting.
02
Drugs
eflornithine
03
Conditions
Ewing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT07321912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321912.